IN2014CN03749A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03749A
IN2014CN03749A IN3749CHN2014A IN2014CN03749A IN 2014CN03749 A IN2014CN03749 A IN 2014CN03749A IN 3749CHN2014 A IN3749CHN2014 A IN 3749CHN2014A IN 2014CN03749 A IN2014CN03749 A IN 2014CN03749A
Authority
IN
India
Prior art keywords
compositions
methods compounds
symptom
animal
protein
Prior art date
Application number
Other languages
English (en)
Inventor
Susan M Freier
Sanjay Bhanot
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of IN2014CN03749A publication Critical patent/IN2014CN03749A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
IN3749CHN2014 2011-10-25 2012-10-25 IN2014CN03749A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551378P 2011-10-25 2011-10-25
PCT/US2012/061984 WO2013063313A1 (fr) 2011-10-25 2012-10-25 Modulation antisens de l'expression de gccr

Publications (1)

Publication Number Publication Date
IN2014CN03749A true IN2014CN03749A (fr) 2015-09-25

Family

ID=48168513

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3749CHN2014 IN2014CN03749A (fr) 2011-10-25 2012-10-25

Country Status (14)

Country Link
US (2) US8901098B2 (fr)
EP (1) EP2771463A4 (fr)
JP (1) JP2015501155A (fr)
KR (1) KR20140084232A (fr)
CN (1) CN103906838A (fr)
AU (2) AU2012328680A1 (fr)
BR (1) BR112014009790A2 (fr)
CA (1) CA2853373A1 (fr)
HK (1) HK1201555A1 (fr)
IL (1) IL232183A0 (fr)
IN (1) IN2014CN03749A (fr)
MX (1) MX350944B (fr)
RU (1) RU2014119787A (fr)
WO (1) WO2013063313A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
KR102149571B1 (ko) 2014-05-01 2020-08-31 아이오니스 파마수티컬즈, 인코포레이티드 성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
LT3283080T (lt) * 2015-04-16 2020-05-25 Ionis Pharmaceuticals, Inc. C9orf72 ekspresijos moduliavimo kompozicijos
CN108026529A (zh) * 2015-09-30 2018-05-11 Ionis制药公司 组合疗法
US10083668B2 (en) 2016-03-09 2018-09-25 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device, display device, and electronic device
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
HRP20230023T1 (hr) 2017-10-20 2023-03-17 Dicerna Pharmaceuticals, Inc. Postupci liječenja infekcije hepatitisom b
US11661603B2 (en) 2018-01-16 2023-05-30 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting ALDH2 expression
CN113692444A (zh) 2019-02-12 2021-11-23 迪克纳制药公司 用于抑制cyp27a1的表达的方法和组合物
CN109680095A (zh) * 2019-02-25 2019-04-26 广西中医药大学 一种鉴定苦玄参品种的ssr引物组合物及其品种鉴定方法
AU2020252560A1 (en) 2019-04-04 2021-10-28 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression in the central nervous system
EP4121536A1 (fr) 2020-03-18 2023-01-25 Dicerna Pharmaceuticals, Inc. Compositions et procédés d'inhibition de l'expression de l'angptl3
CA3190481A1 (fr) 2020-08-04 2022-02-10 Dicerna Pharmaceuticals, Inc. Compositions et methodes d'inhibition de l'expression de plp1
MX2023001541A (es) 2020-08-04 2023-03-08 Dicerna Pharmaceuticals Inc Administracion sistemica de oligonucleotidos.
TW202221120A (zh) 2020-08-04 2022-06-01 美商黛瑟納製藥公司 用於治療代謝症候群之組成物及方法
WO2022032288A1 (fr) 2020-08-05 2022-02-10 Dicerna Pharmaceuticals, Inc. Compositions et méthodes d'inhibition de l'expression de lpa
KR20230104880A (ko) 2020-10-08 2023-07-11 다이서나 파마수이티컬, 인크. 올리고뉴클레오티드의 신경교세포로의 선택적 전달
CN117120612A (zh) 2021-04-12 2023-11-24 勃林格殷格翰国际有限公司 用于抑制己酮糖激酶（khk）的组合物及方法
IL307625A (en) 2021-04-14 2023-12-01 Dicerna Pharmaceuticals Inc Compounds and methods for modulating pnpla3 expression
US11578329B2 (en) 2021-04-19 2023-02-14 Novo Nordisk A/S Compositions and methods for inhibiting nuclear receptor subfamily 1 group H member 3 (NR1H3) expression
WO2022248665A1 (fr) 2021-05-28 2022-12-01 Novo Nordisk A/S Compositions et méthodes pour inhiber l'expression du composant 1 réducteur d'amidoxime mitochondriale (marc1)
US20230107967A1 (en) 2021-08-25 2023-04-06 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting alpha-1 antitrypsin expression
WO2023102469A2 (fr) 2021-12-01 2023-06-08 Dicerna Pharmaceuticals, Inc. Compositions et procédés de modulation de l'expression d'apoc3
WO2023201043A1 (fr) 2022-04-15 2023-10-19 Dicerna Pharmaceuticals, Inc. Compositions et procédés de modulation de l'activité de scap
TW202400792A (zh) 2022-05-12 2024-01-01 美商戴瑟納製藥股份有限公司 用於抑制ｍａｐｔ表現之組合物及方法
WO2023220351A1 (fr) 2022-05-13 2023-11-16 Dicerna Pharmaceuticals, Inc. Compositions et procédés d'inhibition de l'expression de snca
TW202400193A (zh) 2022-06-24 2024-01-01 丹麥商諾佛 儂迪克股份有限公司 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
AU7802587A (en) 1986-08-01 1988-02-24 Genetics Institute Inc. High level inducible expression of heterologous genes
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
US5872242A (en) 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
RU95114435A (ru) 1992-12-14 1997-05-20 Ханивелл Инк. (Us) Система с бесщеточным двигателем постоянного тока
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US7875733B2 (en) 2003-09-18 2011-01-25 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
WO1999015643A2 (fr) 1997-09-25 1999-04-01 University Of Florida COMPOSITIONS OLIGONUCLEOTIDIQUES ANTISENSE CIBLEES SUR L'ARNm DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE ET METHODES D'UTILISATION
US6238921B1 (en) 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US20030203862A1 (en) 1998-03-26 2003-10-30 Miraglia Loren J. Antisense modulation of MDM2 expression
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6821724B1 (en) 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
GB9907048D0 (en) 1999-03-27 1999-05-19 Karobio Ab Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
CA2393045A1 (fr) 1999-12-07 2001-06-14 Sumitomo Chemical Co., Ltd. Er.alpha. mutants et systeme de test pour transactivation
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
GB0008936D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Vectors
US6649341B1 (en) 2000-04-19 2003-11-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Human glucocorticoid receptor 1A promoter and splice variants
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US7227007B2 (en) 2000-12-28 2007-06-05 Asahi Kasei Pharma Corporation NF-κB activating gene
WO2003008583A2 (fr) 2001-03-02 2003-01-30 Sagres Discovery Nouvelles compositions et methodes relatives au cancer
WO2003070888A2 (fr) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Inhibition de l'expression du gene checkpoint kinase-1 (chk-1) mediee par l'arn i a l'aide d'un acide nucleique a interference proche
WO2002096943A1 (fr) 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Genes activant le stat6
US20030092616A1 (en) 2001-05-25 2003-05-15 Akio Matsuda STAT6 activation gene
WO2003004602A2 (fr) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Oligonucleotides chimeres resistants a la nuclease
WO2003008578A2 (fr) 2001-07-20 2003-01-30 Board Of Trustees Of The University Of Illinois Agents reactifs et procedes d'identification de genes cibles dans le traitement du cancer
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US20060088828A1 (en) 2002-01-23 2006-04-27 Harris Peter C Polycystic kidney disease nucleic acids and proteins
EP1472265A4 (fr) 2002-02-20 2005-06-15 Sirna Therapeutics Inc Inhibition mediee par interference d'arn de l'expression du gene de la proteine ezh2 du groupe polycomb a l'aide d'un acide nucleique court interferent (sina)
JP2003265184A (ja) 2002-03-18 2003-09-24 Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho 被検者におけるグルココルチコイド製剤の有効性の検査方法
NZ546806A (en) 2002-03-27 2007-03-30 Aegera Therapeutics Inc Antisense IAP nucleobase oligomers and uses thereof
SI2264172T1 (sl) 2002-04-05 2017-12-29 Roche Innovation Center Copenhagen A/S Oligomerne spojine za modulacijo izražanja HIF-1alfa
WO2003099215A2 (fr) 2002-05-20 2003-12-04 Pharmacia Corporation Modulation antisens de l'expression du recepteur de glucocorticoide
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US7122527B2 (en) 2002-08-16 2006-10-17 Rexahn Corporation Use of antisense oligonucleotides to inhibit the expression of human Akt-1
WO2004034969A2 (fr) 2002-08-19 2004-04-29 Regulome Corporation Sites fonctionnels
ATE478142T1 (de) 2002-08-21 2010-09-15 Univ British Columbia Behandlung von melanomen durch reduktion der clusterin menge
CA2504929C (fr) 2002-11-05 2014-07-22 Charles Allerson Compositions comprenant des nucleosides modifies en 2' de substitution destinees a la modulation de gene
CA2504694C (fr) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Composes oligomeres renfermant un substitut de sucre polycyclique et compositions intervenant dans la modulation genique
EP1560931B1 (fr) 2002-11-14 2011-07-27 Dharmacon, Inc. Arnsi fonctionnel et hyperfonctionnel
NZ540631A (en) 2002-11-25 2006-12-22 Den Kgl Porcine polymorphisms and methods for detecting them
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
WO2004106356A1 (fr) 2003-05-27 2004-12-09 Syddansk Universitet Derives de nucleotides fonctionnalises
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
EP1661905B9 (fr) 2003-08-28 2012-12-19 IMANISHI, Takeshi Nouveaux acides nucleiques artificiels de type a liaison n-o reticulee
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20070009899A1 (en) 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
US7622453B2 (en) 2003-12-23 2009-11-24 Santaris Pharma A/S Oligomeric compounds for the modulation of Bcl-2
WO2005071080A2 (fr) 2004-01-20 2005-08-04 Isis Pharmaceuticals, Inc. Modulation de l'expression du récepteur glucocorticoïde
EP1799859B1 (fr) 2004-09-17 2014-07-02 Isis Pharmaceuticals, Inc. Oligonucleotides antisens ameliores
US20080125583A1 (en) 2005-02-11 2008-05-29 International Business Machines Corporation Ribonucleic acid interference molecules
JP2006320271A (ja) * 2005-05-20 2006-11-30 Tokyo Institute Of Technology 低分子化合物とタンパク質の結合評価方法
CN101313066A (zh) * 2005-09-19 2008-11-26 强生医药研究及开发有限责任公司 糖皮质激素受体表达的调节
CN102766630B (zh) 2006-01-27 2014-05-07 Isis制药公司 6-修饰的双环核酸类似物
EP2505646A1 (fr) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Composés et procédés pour moduler lýexpression de CRP
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
AU2008260277C1 (en) 2007-05-30 2014-04-17 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (fr) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique bicyclique carbocylique
ES2376507T5 (es) 2007-07-05 2015-08-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos 6-disustituidos

Also Published As

Publication number Publication date
RU2014119787A (ru) 2015-12-10
US9567587B2 (en) 2017-02-14
AU2018203564A1 (en) 2018-06-07
MX2014005067A (es) 2014-08-22
US8901098B2 (en) 2014-12-02
US20130150425A1 (en) 2013-06-13
MX350944B (es) 2017-09-26
EP2771463A4 (fr) 2015-09-09
CN103906838A (zh) 2014-07-02
CA2853373A1 (fr) 2013-05-02
EP2771463A1 (fr) 2014-09-03
WO2013063313A1 (fr) 2013-05-02
AU2012328680A1 (en) 2014-05-01
US20150141493A1 (en) 2015-05-21
HK1201555A1 (en) 2015-09-04
IL232183A0 (en) 2014-06-30
KR20140084232A (ko) 2014-07-04
BR112014009790A2 (pt) 2018-05-15
JP2015501155A (ja) 2015-01-15

Similar Documents

Publication Publication Date Title
IN2014CN03749A (fr)
IN2014CN02736A (fr)
MX2012012624A (es) Modulacion de la expresion de transtiretina.
IL266001B (en) Bile acid recycling inhibitors for the treatment of biliary stasis liver disease and hyperkalemia
MX353152B (es) Modulación de expresión de huntingtina.
MY162715A (en) Modulation of apolipoprotein ciii (apociii) expression
EP3489360A3 (fr) Modulation de l'arn retenu nucléaire
MX2016008462A (es) Modulacion de la expresion similar a la angiopoyetina tipo 3.
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
WO2012174476A3 (fr) Modulation antisens de l'expression du récepteur 4 du facteur de croissance fibroblastique
EP2766474A4 (fr) Inhibition et amélioration de la re-programmation par des enzymes de modification de la chromatine
EP2684167A4 (fr) Compositions et méthodes utiles dans le traitement de maladies
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
HK1201771A1 (en) Compositions and methods for treating alzheimers disease
WO2012145254A9 (fr) Procédés d'utilisation d'inhibiteurs de rorϒt pour traiter une maladie
CL2014000557A1 (es) Composicion antioxidante mejorada para alimentacion animaly constituyentes de alimentacion animal; y metodo para mejorar dicha composicion.
HRP20180687T1 (hr) Kompozicije i metode za liječenje celijakije spru
EP2723351A4 (fr) Compositions et procédés d'inhibition de l'expression de gènes de protéine c (proc)
UY34070A (es) Método y composición para tratamiento de semillas.
EA201500752A1 (ru) Способ лечения заболеваний
HK1184642A1 (en) Date pit composition for the treatment of animals
LU91877B1 (en) Method to predict the presence of itaconic Acid, IRG1 and/or protein IRG1 in a subject and pharmaceutical composition for performing gene therapy
EP2702997A4 (fr) Méthode et composition destinées à améliorer l'absorption d'agents thérapeutiques par des cellules cibles
HUP1100535A2 (en) Pharmaceutical composition for enhancement of stem cell treatment